Edwards has studied Resilia in two pre-market clinical trials, combining outcomes for a total of 904 patients and more than 3,800 patient years of follow-up that support the tissue replacement platform.
Are we taking about Edward’s 904/3800 patients vs AVR’s 5 patients and another 5 in the wing?
If it’s the case it is understandable why the big companies are not interested in AVR products as yet,
Edwards has studied Resilia in two pre-market clinical trials,...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.80 |
Change
-0.200(1.67%) |
Mkt cap ! $249.4M | |||
| Open | High | Low | Value | Volume |
| $12.49 | $12.99 | $11.63 | $303.4K | 24.97K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1100 | $11.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.15 | 849 | 1 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |